Analysts Set Heron Therapeutics, Inc. (NASDAQ:HRTX) Price Target at $34.67


Share on StockTwits

Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $34.67.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 7th. Stifel Nicolaus restated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, September 8th. SVB Leerink boosted their price target on shares of Heron Therapeutics from $21.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 2nd. BidaskClub upgraded shares of Heron Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, December 23rd. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, November 23rd.

Hedge funds have recently bought and sold shares of the business. Prime Capital Investment Advisors LLC increased its position in Heron Therapeutics by 90.5% during the third quarter. Prime Capital Investment Advisors LLC now owns 2,000 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 950 shares during the last quarter. Smith Asset Management Group LP increased its position in Heron Therapeutics by 32.4% during the third quarter. Smith Asset Management Group LP now owns 3,720 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 910 shares during the last quarter. Pacer Advisors Inc. bought a new position in Heron Therapeutics during the third quarter valued at $59,000. PNC Financial Services Group Inc. increased its position in Heron Therapeutics by 53.3% during the second quarter. PNC Financial Services Group Inc. now owns 4,136 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 1,438 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in Heron Therapeutics by 407.2% during the third quarter. Nisa Investment Advisors LLC now owns 4,235 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 3,400 shares during the last quarter. Institutional investors and hedge funds own 93.00% of the company’s stock.

Heron Therapeutics stock opened at $21.17 on Wednesday. The stock has a market cap of $1.92 billion, a P/E ratio of -8.57 and a beta of 1.49. Heron Therapeutics has a 1 year low of $9.60 and a 1 year high of $24.76. The firm’s 50 day moving average price is $18.62 and its 200-day moving average price is $16.69.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.01). The company had revenue of $19.97 million for the quarter, compared to the consensus estimate of $18.00 million. Heron Therapeutics had a negative net margin of 216.18% and a negative return on equity of 65.06%. Sell-side analysts expect that Heron Therapeutics will post -2.55 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: Cost of Debt

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.